Acrobiosystems for English
icon_bulk_orderBulk inquiry/Quick order
user
  1. Dashboard
  2. My Profile
  3. My Address
  4. My Orders
  5. Acro Membership
Login Register
Promotion
Recombinant Proteins ClearClear history
Recombinant Proteins CloseClose
Browse Products By Molecule Name a-zA-Z
TL1A Hot |GMP Cytokines Hot |FcRn Binding Kit (TR-FRET) New |Claudin 18.2
0
There is no goods in the shopping cart !
My Cart|Secure Checkout
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > Apo-A1

Apo-A1

Brief Information

Name:Apolipoprotein A-I
Target Synonym:Epididymis Secretory Sperm Binding Protein,Apolipoprotein A-I(1-242),APOA1,ProapoA-I,Apo-AI,Apolipoprotein A1,Apo(A),ApoA-I,Apolipoprotein A-I,HPALP2
Number of Launched Drugs:0
Number of Drugs in Clinical Trials:3
Lastest Research Phase:Phase 2 Clinical

Product ListCompare or Buy

Product> Filter Results
By Product Status:
By Product Category:
By Species:
By Tag:
By Conjugate:
Cat. No. Species Product Description Structure Purity Feature
AP1-H5225 Human Human Apo-A1 Protein, His Tag
AP1-H5225-structure
AP1-H5225-sds
ACRO Quality

Synonym Name

Apolipoprotein A-I,APOA1,MGC117399

Background

ApoA1 is also known as apolipoprotein A-I, ApoA-I , and is the major protein component of high density lipoprotein (HDL) in plasma. It has a specific role in lipid metabolism. Chylomicrons secreted from the intestinal enterocyte also contain ApoA1 but it is quickly transferred to HDL in the bloodstream. The protein promotes cholesterol efflux from tissues to the liver for excretion. It is a cofactor for lecithin cholesterol acyltransferase (LCAT) which is responsible for the formation of most plasma cholesteryl esters. ApoA-I was also isolated as a prostacyclin (PGI2) stabilizing factor, and thus may have an anticlotting effect. Defects in the gene encoding it are associated with HDL deficiencies, including Tangier disease, and with systemic non-neuropathic amyloidosis. In addition, it has been shown that ApoA1 is implicated in the anti-endotoxin function of HDL via interaction with lipopolysaccharide or endotoxin.

Clinical and Translational Updates

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
Zerlasiran SLN-360 Phase 2 Clinical Silence Therapeutics Plc Atherosclerosis; Dyslipidemias; Cardiovascular Diseases; Hyperlipidemias; Lipid Metabolism Disorders Details
Fx-5A Fx-5A Phase 1 Clinical Kinemed Inc Cardiovascular Diseases Details

This web search service is supported by Google Inc.

totop
Call us
Call us
North America:
+1 800-810-0816 (Toll Free)
Asia & Pacific:
+86 400-682-2521
Email
Email
order@acrobiosystems.com
Fax
Fax
+1 888-377-6111
Address
Address
1 Innovation Way, Newark, DE 19711, USA
linkedin twitter facebook youtube

Leave a message

Copyright © 2017 ACROBiosystems. All Rights Reserved
|Related Links|Privacy Policy|Terms and Conditions|Legal|Sitemap